Algert Global LLC Sells 127,260 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Algert Global LLC reduced its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 92.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the biopharmaceutical company's stock after selling 127,260 shares during the period. Algert Global LLC's holdings in Revance Therapeutics were worth $26,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Arizona State Retirement System raised its holdings in Revance Therapeutics by 27.6% during the second quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 5,996 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Revance Therapeutics by 67.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 16,981 shares of the biopharmaceutical company's stock worth $84,000 after acquiring an additional 6,826 shares in the last quarter. Sei Investments Co. raised its holdings in Revance Therapeutics by 52.5% during the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 7,628 shares in the last quarter. California State Teachers Retirement System raised its holdings in Revance Therapeutics by 9.8% during the first quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company's stock worth $480,000 after acquiring an additional 8,668 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Revance Therapeutics by 29.4% in the second quarter. The Manufacturers Life Insurance Company now owns 42,296 shares of the biopharmaceutical company's stock valued at $109,000 after buying an additional 9,601 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Revance Therapeutics Stock Up 0.4 %

Shares of RVNC stock traded up $0.02 during trading hours on Friday, reaching $5.28. The company's stock had a trading volume of 1,048,243 shares, compared to its average volume of 2,808,866. The firm's 50 day simple moving average is $5.78 and its 200-day simple moving average is $4.26. The company has a market capitalization of $551.49 million, a price-to-earnings ratio of -1.45 and a beta of 0.98. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $9.90.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.12. The business had revenue of $65.39 million during the quarter, compared to analyst estimates of $66.30 million. The company's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.80) EPS. Sell-side analysts predict that Revance Therapeutics, Inc. will post -1.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

RVNC has been the topic of several research analyst reports. Needham & Company LLC lowered Revance Therapeutics from a "moderate buy" rating to a "hold" rating in a research note on Tuesday, August 13th. Piper Sandler lowered Revance Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 12th. HC Wainwright lowered Revance Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 13th. Guggenheim reiterated a "neutral" rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Finally, Barclays reiterated an "equal weight" rating and set a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $10.29.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.